D910FC00001: An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
This is a rollover clinical research study for subjects who are being treated or have previously been treated with the study drug durvalumab in another clinical research study and are still being followed-up regarding their health status.
Patients must be 18 years of age or older
Patient received durvalumab monotherapy and/or durvalumab containing combination in an AstraZeneca/MedImmune-sponsored parent clinical study that is approved for enrollment into this study
Patients who received durvalumab in combination with any other approved or investigational anticancer agents in the parent clinical study must have completed or discontinued all other anticancer therapy (beyond durvalumab regimen).
Patient must be willing and able to provide written informed consent and to comply with scheduled visits and other study procedures.